Alejandro Natividad, MD
Psychiatry · Amarillo, TXNPI 1467436014
Payments from drug & device makers
Across 554 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$716
- Johnson & Johnson$664
- Takeda Pharmaceuticals U.S.A., Inc.$514
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$506
- plus $3K from 25 others
What the payments were for
- Consulting fees$2,42022%
- Speaking & faculty fees$180%
- Food & beverage$8,09375%
- Education$3103%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 57 | $3,350 |
| Neurocrine Biosciences, Inc. | 188 | $2,441 |
| Otsuka America Pharmaceutical, Inc. | 46 | $716 |
| Johnson & Johnson | 41 | $664 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $514 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $506 |
| Tris Pharma Inc | 25 | $394 |
| AbbVie(2 entities) | 14 | $272 |
| Sunovion Pharmaceuticals Inc. | 29 | $267 |
| Alkermes, Inc. | 13 | $238 |
| Biogen | 8 | $163 |
| Kyowa Kirin, Inc. | 8 | $160 |
| Novartis | 8 | $154 |
| Lundbeck LLC | 9 | $147 |
| Supernus Pharmaceuticals, Inc. | 7 | $137 |
| Jazz Pharmaceuticals Inc. | 4 | $85 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $65 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Acorda Therapeutics, Inc | 3 | $57 |
| Harmony Biosciences LLC | 2 | $51 |
| UCB, Inc. | 2 | $50 |
| Pfizer | 2 | $50 |
| Sanofi | 2 | $45 |
| Lilly USA, LLC | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Genentech USA, Inc. | 2 | $42 |
| EMD Serono, Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
| Upsher-smith Laboratories LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $17 |
| SK Life Science, Inc. | 1 | $17 |
How this compares
$10,842 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 151 | $1,257,610 |
| AustedoDeutetrabenazine | 18 | $227,685 |
| Invega SustennaPaliperidone Palmitate | 51 | $99,197 |
| AristadaAripiprazole Lauroxil | 36 | $83,768 |
| VraylarCariprazine Hcl | 35 | $78,781 |
| LybalviOlanzapine/Samidorphan Malate | 40 | $70,898 |
| Abilify MaintenaAripiprazole | 16 | $42,226 |
| TrintellixVortioxetine Hydrobromide | 25 | $27,538 |
| SaphrisAsenapine Maleate | 12 | $12,077 |
| Aripiprazole | 47 | $10,965 |
| Lurasidone Hcl | 27 | $6,240 |
| Duloxetine Hcl | 117 | $4,405 |
| Divalproex Sodium ErDivalproex Sodium | 67 | $4,315 |
| Olanzapine | 71 | $3,176 |
| Bupropion XlBupropion Hcl | 94 | $3,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,441 | $1,257,610151 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $3,350 | $227,68518 claims |
| Alkermes, Inc.Aristada, Lybalvi | $238 | $154,66676 claims |
| Johnson & JohnsonInvega Sustenna | $664 | $99,19751 claims |
| AbbVieVraylar, Saphris | $272 | $90,85847 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $716 | $42,22616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $514 | $27,53825 claims |
| Lilly USA, LLCOlanzapine | $44 | $3,17671 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Amarillo
- James RushAmarillo$514K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.